Entera Bio (ENTX) Revenue (2018 - 2025)

Entera Bio (ENTX) has reported Revenue for 7 consecutive years, with $42000.0 the latest figure, recorded in Q1 2025.

• Quarterly Revenue changed N/A year-over-year to $42000.0 in Q1 2025, while the trailing twelve-month figure through Dec 2025 was $42000.0 (down 76.8% YoY) and the FY2025 annual result came in at $42000.0, down 76.8% from the prior year.
• Revenue slipped to $42000.0 in Q1 2025 per ENTX's latest filing, from $82000.0 in the prior quarter.
• Over the last five years, Revenue for ENTX reached as high as $165000.0 in Q4 2021 and fell as low as $8000.0 in Q3 2022.
• A 4-year average of $77333.3 and a median of $62500.0 in 2022 frame the typical range for Revenue.
• Annual changes were most pronounced in 2021 — Revenue jumped 109.62% — and 2022, when it tumbled 94.29%.
• Year by year, Revenue stood at $165000.0 in 2021, then tumbled by 91.52% to $14000.0 in 2022, then jumped by 485.71% to $82000.0 in 2024, then plunged by 48.78% to $42000.0 in 2025.
• According to Business Quant data, Revenue over the past three periods registered $42000.0, $82000.0, and $42000.0 for Q1 2025, Q4 2024, and Q3 2024 respectively.